News | May 24, 2023
Biocon posts Q4 FY23 consolidated PAT at Rs. 313.2 Cr
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Subscribe To Our Newsletter & Stay Updated
